Thursday, 15 October 2026European Markets

HYDROGENPRO Stock Bullish Momentum With A 9.42% Rise Today

Loading stream...

(VIANEWS) - The Market ended the session with HYDROGENPRO (HYPRO.OL) rising 9.42% to kr7.78 on Wednesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.25% to kr1,441.83, following the last session's downward trend on what was a somewhat up trend exchanging session today.

HYDROGENPRO's last close was kr7.11, 61.4% below its 52-week high of kr18.42.

About HYDROGENPRO

HydrogenPro ASA engages in designing and delivering hydrogen technology and systems in Norway, Europe, the United States, and the Asia Pacific. It offers high-pressure alkaline electrolyzers. The company serves synthetic aviation fuel, refinery/decarbonization, power to gas, balancing the grid, steel production, fertilizer/ammonia, and shipping markets. HydrogenPro ASA was incorporated in 2013 and is headquartered in Porsgrunn, Norway.

Earnings Per Share

As for profitability, HYDROGENPRO has a trailing twelve months EPS of kr-2.52.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -32.47%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HYDROGENPRO's stock is considered to be overbought (>=80).

Volatility

HYDROGENPRO's last week, last month's, and last quarter's current intraday variation average was a negative 6.25%, a negative 1.18%, and a positive 2.32%.

HYDROGENPRO's highest amplitude of average volatility was 6.93% (last week), 2.46% (last month), and 2.32% (last quarter).

Sales Growth

HYDROGENPRO's sales growth for the next quarter is negative 80.6%.

Yearly Top and Bottom Value

HYDROGENPRO's stock is valued at kr7.78 at 22:32 EST, way below its 52-week high of kr18.42 and above its 52-week low of kr7.75.

More news about HYDROGENPRO (HYPRO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com